China Resources Boya Bio-pharmaceutical Group (300294.SZ): Human vasculitis factor for hemophilia approved for clinical trials after process upgrade.

China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that recently, the company received the approval letter for the clinical trial of human coagulation factor for hemophilia A issued by the National Medical Products Administration (referred to as "NMPA"). The approval letter number is 2026LP02173. This approval is for the re-application after completing core production process upgrades for the product, and it is not a new application. The re-approval of the clinical trial for human coagulation factor for hemophilia A after process upgrades is an important optimization of the company's core production technology, laying a solid foundation for the smooth progress of the clinical trial. The approval of this clinical trial will further stimulate the innovation enthusiasm of the research and development team, improve the company's product pipeline layout in the field of rare bleeding disorders, and provide strong support for enriching the blood product line and enhancing core market competitiveness.